Bausch+Lomb Results Presentation Deck
Total Bausch + Lomb P&L¹ (GAAP) - FY22
Bausch + Lomb
Vision Care Revenue
Surgical Revenue
Ophthalmic Pharmaceuticals Revenue
Total Revenue
Gross Profit
Gross Margin
R&D
R&D percent of Revenues
SG&A
SG&A percent of Revenues
Operating Income
Depreciation
Stock Based Compensation
Net Income Attributable to Bausch
+ Lomb
Net Income Margin
EPS Attributable to Bausch + Lomb³
FY22
BAUSCH + LOMB 3. Presented on an adjusted basis after giving effect to the IPO.
$2,373M
$718M
$677M
$3,768M
$2,004 M
53.2%
$307M
8.1%
$1,478M
39.2%
$207M
$135M
$62M
$6M
0.2%
$0.02
FY21
$2,343M
$718M
$704M
$3,765M
$1,994M
53.0%
$271M
7.2%
$1,389M
36.9%
$329M
$123M
$62M
$182M
4.8%
$0.52
1. Products with sales outside the United States impacted by F/X changes.
2. This is a non-GAAP measure or ratio. See Slide 2 and Appendix for further information on non-GAAP measures and ratios.
Reported Change
Organic revenue growth/change, a non-GAAP ratio, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if
applicable) excluding the impact of acquisitions, divestitures and discontinuations.
1%
0%
(4%)
0%
1%
20 bps
(13%)
(6%)
(37%)
10%
0%
(97%)
Constant Currency²
6%
6%
0%
5%
5%
(16%)
(11%)
(31%)
15%
0%
(103%)
Organic Change 2,4
6%
8%
0%
5%
14View entire presentation